Standard BioTools (NASDAQ:LAB) Posts Earnings Results, Misses Estimates By $0.04 EPS

Standard BioTools (NASDAQ:LAB) posted its quarterly earnings data on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.04), Zacks reports. Standard BioTools had a negative return on equity of 20.23% and a negative net margin of 69.08%. Standard BioTools updated its FY 2025 guidance to EPS.

Standard BioTools Price Performance

Shares of Standard BioTools stock traded down $0.05 during trading on Tuesday, reaching $1.19. 1,727,149 shares of the stock traded hands, compared to its average volume of 1,658,663. Standard BioTools has a 52-week low of $0.92 and a 52-week high of $2.32. The business has a fifty day simple moving average of $1.31 and a two-hundred day simple moving average of $1.23. The company has a market capitalization of $454.57 million, a price-to-earnings ratio of -3.72 and a beta of 1.31.

Insider Buying and Selling

In other news, Director Casdin Partners Master Fund, L purchased 250,000 shares of the business’s stock in a transaction on Wednesday, September 3rd. The stock was acquired at an average price of $1.27 per share, for a total transaction of $317,500.00. Following the acquisition, the director directly owned 60,525,000 shares of the company’s stock, valued at $76,866,750. This represents a 0.41% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders purchased 1,233,220 shares of company stock worth $1,546,446 over the last three months. 23.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LAB. BNP Paribas Financial Markets grew its holdings in shares of Standard BioTools by 50.3% in the second quarter. BNP Paribas Financial Markets now owns 29,826 shares of the company’s stock valued at $36,000 after purchasing an additional 9,986 shares in the last quarter. Jane Street Group LLC bought a new position in Standard BioTools during the second quarter valued at $43,000. Cerity Partners LLC grew its stake in shares of Standard BioTools by 70.2% in the 2nd quarter. Cerity Partners LLC now owns 37,501 shares of the company’s stock worth $45,000 after buying an additional 15,470 shares in the last quarter. Prudential Financial Inc. increased its holdings in shares of Standard BioTools by 72.7% in the 2nd quarter. Prudential Financial Inc. now owns 39,307 shares of the company’s stock worth $47,000 after buying an additional 16,541 shares during the last quarter. Finally, Creative Planning raised its position in shares of Standard BioTools by 56.6% during the 2nd quarter. Creative Planning now owns 61,102 shares of the company’s stock valued at $73,000 after buying an additional 22,082 shares in the last quarter. 53.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on LAB shares. Weiss Ratings restated a “sell (d-)” rating on shares of Standard BioTools in a research note on Wednesday, October 8th. TD Cowen cut shares of Standard BioTools from a “buy” rating to a “hold” rating and set a $1.55 target price on the stock. in a research note on Wednesday, August 13th. Wall Street Zen upgraded shares of Standard BioTools from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Finally, Cowen cut shares of Standard BioTools from a “buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $1.55.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.